<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885610</url>
  </required_header>
  <id_info>
    <org_study_id>C005 SLECLLI</org_study_id>
    <nct_id>NCT02885610</nct_id>
  </id_info>
  <brief_title>Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)</brief_title>
  <official_title>A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to initially access the safety and effectivity of RC18 combined
      with standard treatment and Placebo combined with standard therapy in subjects with Moderate
      to severe SLE, Besides ,to provide dose basis for follow-up clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLE Responder Index (SRI) Response Rate</measure>
    <time_frame>Week 48</time_frame>
    <description>At Week 48, the percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in PGA</measure>
    <time_frame>Week 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day During Weeks 44 Through 48</measure>
    <time_frame>Week 44 through 48</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Change From Baseline in Serological Examination Index(IgG、IgA、IgM) CD19+、Anti-dsDNA 、Complent C3、C4</measure>
    <time_frame>week 48</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 80 mg plus standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 160 mg plus standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 240 mg plus standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 80 mg plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )</description>
    <arm_group_label>RC18 80 mg plus standard therapy</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160 mg plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )</description>
    <arm_group_label>RC18 160 mg plus standard therapy</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 240 mg plus standard therapy</intervention_name>
    <description>Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )</description>
    <arm_group_label>RC18 240 mg plus standard therapy</arm_group_label>
    <other_name>Standard therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active SLE disease，and at least according with 4 of the 11 items of the American
             College of Rheumatology (ACR) criteria 1997.

          -  Age &amp; Gender: Male or female between 18 and 65 years of age inclusive，and the sex
             ratio is not limited

          -  Signed informed consent form，willing or able to participate in all required study
             evaluations and procedures.

          -  SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE
             Disease Activity Index) score ≥ 8 during the screening period.and if there is
             hypocomlement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be
             at least 6 at screening .

          -  Autoantibody-positive

          -  on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted
             of any of the following (alone or in combination): cortical
             hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any
             immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate
             ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin ).

        Exclusion Criteria:

          -  Severe lupus nephritis within two months(designed as:Urine protein&gt;6g/24h or serum
             creatinine ( SCr）&gt;2.5mg/dL or 221umol/L ) or needing for hemodialysis or recepting
             high dose cortical hormone ≥14 days( metacortandracin&gt;100mg/d or equivalent)

          -  Central nervous system disease caused by SLE or non SLE within two months (including
             epilepsy， mental disease，organic encephalopathy syndrome，cerebrovascular accident,
             encephalitis, central nervous system vasculitis）;

          -  there are serious heart, liver, kidney and other important organs and blood, endocrine
             system diseases and medical history;

        Evaluation criteria for severity :

          1. Alanine aminotransferase（ALT）or aspartate aminotransferase (AST) ≥2 upper limit of
             normal (ULN);

          2. Creatinine Clearance (Ccr)&lt;30ml/min;

          3. White Blood Cell Count(WBCs)&lt;2.5x 10(9)/L;

          4. hemoglobin&lt;85g/L;

          5. Platelets&lt;50x 10(9)/L.

               -  Have a historically active hepatitis or active hepatitis or medical
                  history,hepatitis B :Patients with positive HBsAg are excluded.;Hepatitis C:
                  Patients with hepatitis C antibody positive are excluded;

               -  Immune deficiency, uncontrolled severe infection and patients with active or
                  recurrent peptic ulcer;

               -  Pregnant , lactating women and men or women who have birth plans in the past 12
                  months ;

               -  Have a history of allergic reaction to human biological medicines.

               -  Receipt of live vaccine within 1 month;

               -  Have participated in any clinical trial in the first 28 days of the initial
                  screening or 5 times half-life period of the study compound (taking the time for
                  the elderly).

               -  Have received treatment with B cell targeted therapy such as Rituximab or
                  Epratuzumab etc.

               -  Receipt of anti-tumor necrosis factor、interleukin receptor antagonist；

               -  Receipt of IV immunoglobulin（IVIG）,prednisone&gt;100mg/d more than 14 days or plasma
                  exchange;

               -  There are active infections (such as herpes zoster, human immunodeficiency virus
                  (HIV) virus infection, active tuberculosis, etc.) during the screening period;

               -  Patients have depression or the significant suicide ideation;

               -  Investigator considers candidates not appropriating for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengchun Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghua Xiao</last_name>
    <phone>86-010-58076833</phone>
    <email>xiaosir522@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengchun Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

